ARGX argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.…
Industry Peers
BiotechnologyKey Statistics
About argenx (EBR: ARGX)
›
argenx (EBR: ARGX) is listed on Euronext Brussels, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1,863 employees.
The shares were at 858.20 EUR on 19 November 2026, up 7.6% over 52 weeks. Its 52-week range is 568.40 EUR to 925.00 EUR: the price is 7.2% below the high and 51.0% above the low.
At a market capitalisation of 53.97B EUR, it trades at 34.5 times trailing earnings and 26.8 times forward earnings. The median trailing P/E of its 12 largest Biotechnology peers is 38.7, a discount of 11% for ARGX.
argenx reports return on equity of 17.6%, an operating margin of 31.9% and revenue up 52.1% year over year.
It holds more cash than debt, a net cash position of 5.14B USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 15 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 1019.41 EUR is 18.8% above the current price. The next earnings report is expected on 25 February 2027.